- Home
- DSGN vs KIO Comparison
DSGN vs KIO Comparison
Compare DSGN & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- KIO
- Stock Information
- Founded
- DSGN 2017
- KIO 2011
- Country
- DSGN United States
- KIO United States
- Employees
- DSGN N/A
- KIO 2400
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- DSGN Health Care
- KIO Finance
- Exchange
- DSGN Nasdaq
- KIO Nasdaq
- Market Cap
- DSGN 353.9M
- KIO 404.1M
- IPO Year
- DSGN 2021
- KIO N/A
- Fundamental
- Price
- DSGN $6.25
- KIO $13.02
- Analyst Decision
- DSGN Hold
- KIO
- Analyst Count
- DSGN 3
- KIO 0
- Target Price
- DSGN $7.00
- KIO N/A
- AVG Volume (30 Days)
- DSGN 208.4K
- KIO 136.5K
- Earning Date
- DSGN 11-07-2024
- KIO 01-01-0001
- Dividend Yield
- DSGN N/A
- KIO 10.82%
- EPS Growth
- DSGN N/A
- KIO N/A
- EPS
- DSGN N/A
- KIO N/A
- Revenue
- DSGN N/A
- KIO N/A
- Revenue This Year
- DSGN N/A
- KIO N/A
- Revenue Next Year
- DSGN N/A
- KIO N/A
- P/E Ratio
- DSGN N/A
- KIO N/A
- Revenue Growth
- DSGN N/A
- KIO N/A
- 52 Week Low
- DSGN $2.25
- KIO $10.52
- 52 Week High
- DSGN $7.77
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- DSGN 52.38
- KIO 28.54
- Support Level
- DSGN $5.55
- KIO $13.56
- Resistance Level
- DSGN $6.45
- KIO $13.78
- Average True Range (ATR)
- DSGN 0.56
- KIO 0.14
- MACD
- DSGN -0.04
- KIO -0.04
- Stochastic Oscillator
- DSGN 57.67
- KIO 15.54
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.